Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aceclofenac + esomeprazole is a fixed-dose combination of two active pharmaceutical ingredients: - **Aceclofenac** is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase (COX) enzymes, thereby reducing the synthesis of prostaglandins responsible for pain and inflammation. It is primarily used to treat conditions such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and acute pain[5][8]. - **Esomeprazole** is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly binding to the H+, K+-ATPase enzyme in gastric parietal cells. This action reduces both basal and stimulated acid production[6]. The combination aims to provide effective pain relief while minimizing gastrointestinal side effects commonly associated with NSAIDs by including a PPI for gastroprotection[3][8]. The formulation improves patient convenience and adherence by combining both agents into one dosage form.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aceclofenac + Esomeprazole.